Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia
about
Evaluation of toxicity in 22 patients treated with subcutaneous interleukin-2, alpha-interferon with and without chemotherapy.Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cellsActivation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengueOverexpression of interleukin-2 by a recombinant herpes simplex virus type 1 attenuates pathogenicity and enhances antiviral immunityIncreased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells.In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment.Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection.Comparison of vascular leak syndrome in mice treated with IL21 or IL2Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.Toxicity as a result of immunostimulation by biologics.Role of IL-2 in cancer immunotherapyProlonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.Acute lethal graft-versus-host reaction induced by major histocompatibility complex class II-reactive T helper cell clones.Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors.Therapy with cultured T cells: principles revisited.Morphological basis of pulmonary edema in mice with cytokine-induced vascular leak syndrome.Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes.The in vivo anti-tumor effect of human recombinant interleukin-6.Regulatory T cells control toxicity in a humanized model of IL-2 therapy.
P2860
Q33349077-170C6CFC-2493-46E4-B022-029D0A49E0FEQ33977597-71807A17-820D-49A3-8889-2A7C8D579575Q34207386-E7EF9B9A-B92B-4C4C-AC98-1231412531FBQ34344404-1E9E0CB6-3A3E-40E5-9739-A0D66D337233Q34563034-DE369025-DC71-4C5E-BD4F-D3AD0F1069B0Q36350708-0853BB33-FF96-4976-81F6-35590AE58128Q36353800-76A4F440-40E9-4C99-96D3-229FFD6A0127Q36595426-0AEAAE88-B3C2-4991-8048-69385846AEA0Q36708311-3760DAA0-41B4-4A54-8F22-F6DBDD4CD4EAQ36788414-D96D83BC-80F5-415C-8546-0950EE75C0DDQ37079072-97293CDD-773A-4F16-8DAE-957CB95710E5Q37686896-4E66D127-1578-4337-971B-F1D8CF06AAC8Q38534445-1031CE9E-D5C3-4523-BA68-98762E5E8748Q40711010-E37525BB-C2DB-4A2A-AC72-C5EBAC4DECE9Q41561740-570F8116-B627-4CB9-8F0E-65F2CDC4C3C4Q41849481-755C9213-E613-407B-9D9A-BEA3F23663A8Q44540464-5B8139CD-B513-4C50-8D6D-85D329448F11Q45021124-E9F38CAC-2F43-4A84-AA20-D323B900BBECQ47131174-63276690-A2B0-4F27-A0AC-BA308DC62E63
P2860
Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Toxicity and therapeutic effic ...... ficacy against murine leukemia
@ast
Toxicity and therapeutic effic ...... ficacy against murine leukemia
@en
type
label
Toxicity and therapeutic effic ...... ficacy against murine leukemia
@ast
Toxicity and therapeutic effic ...... ficacy against murine leukemia
@en
prefLabel
Toxicity and therapeutic effic ...... ficacy against murine leukemia
@ast
Toxicity and therapeutic effic ...... ficacy against murine leukemia
@en
P2860
P356
P1476
Toxicity and therapeutic effic ...... ficacy against murine leukemia
@en
P2093
M A Cheever
P2860
P304
P356
10.1084/JEM.169.1.161
P407
P577
1989-01-01T00:00:00Z